Kintara Therapeutics Company Insiders

KTRA Stock  USD 0.10  0.01  11.73%   
Kintara Therapeutics' insiders are aggressively buying. The analysis of the overall insider sentiment regarding Kintara Therapeutics suggests that vertually all insiders are extremely bullish. Kintara Therapeutics employs about 2 people. The company is managed by 5 executives with a total tenure of roughly 5 years, averaging almost 1.0 years of service per executive, having 0.4 employees per reported executive.

Kintara Therapeutics' Insider Buying Vs Selling

100

 
Selling
 
Buying

Latest Trades

2021-12-08Anthony Scott PraillAcquired 28700 @ 0.68View
2021-12-06Saiid ZarrabianAcquired 11891 @ 0.59View
2021-11-22Laura L JohnsonAcquired 3000 @ 0.74View
Monitoring Kintara Therapeutics' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
  
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kintara Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.
For information on how to trade Kintara Stock refer to our How to Trade Kintara Stock guide.

Kintara Therapeutics Management Team Effectiveness

The company has return on total asset (ROA) of (1.1261) % which means that it has lost $1.1261 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (3.29) %, meaning that it created substantial loss on money invested by shareholders. Kintara Therapeutics' management efficiency ratios could be used to measure how well Kintara Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. At present, Kintara Therapeutics' Return On Capital Employed is projected to increase significantly based on the last few years of reporting. The current year's Return On Assets is expected to grow to about 2 M, whereas Return On Equity is projected to grow to (9.6 M). At present, Kintara Therapeutics' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 5.4 M, whereas Net Tangible Assets are projected to grow to (8.5 M).
As of March 29, 2024, Common Stock Shares Outstanding is expected to decline to about 777.4 K. In addition to that, Net Loss is expected to decline to about (14.2 M)

Kintara Therapeutics Workforce Comparison

Kintara Therapeutics is rated below average in number of employees category among related companies. The total workforce of Health Care industry is now estimated at about 1,011. Kintara Therapeutics adds roughly 2.0 in number of employees claiming only tiny portion of equities under Health Care industry.

Kintara Therapeutics Insider Trading

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Kintara Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Kintara Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Kintara Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Kintara Therapeutics Notable Stakeholders

A Kintara Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Kintara Therapeutics often face trade-offs trying to please all of them. Kintara Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Kintara Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
CPA BBACEO and PresidentidentProfile
BSc CPACFO SecProfile
BBA CPACEO PresProfile
BSc MACoFounder OfficerProfile
Greg JohnsonActing OperationsProfile

About Kintara Therapeutics Management Performance

The success or failure of an entity such as Kintara Therapeutics often depends on how effective the management is. Kintara Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Kintara management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Kintara management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last ReportedProjected for 2024
Return On Capital EmployedM2.1 M
Return On Assets1.9 MM
Return On Equity-10.1 M-9.6 M
The data published in Kintara Therapeutics' official financial statements usually reflect Kintara Therapeutics' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Kintara Therapeutics. For example, before you start analyzing numbers published by Kintara accountants, it's critical to develop an understanding of what Kintara Therapeutics' liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of Kintara Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Kintara Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Kintara Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Kintara Therapeutics. Please utilize our Beneish M Score to check the likelihood of Kintara Therapeutics' management manipulating its earnings.

Kintara Therapeutics Workforce Analysis

Traditionally, organizations such as Kintara Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Kintara Therapeutics within its industry.

Kintara Therapeutics Manpower Efficiency

Return on Kintara Therapeutics Manpower

Revenue Per Employee0.0
Revenue Per Executive0.0
Net Loss Per Employee7.3M
Net Loss Per Executive2.9M
Working Capital Per Employee94K
Working Capital Per Executive37.6K
When determining whether Kintara Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Kintara Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Kintara Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Kintara Therapeutics Stock:
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kintara Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.
For information on how to trade Kintara Stock refer to our How to Trade Kintara Stock guide.
You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.

Complementary Tools for Kintara Stock analysis

When running Kintara Therapeutics' price analysis, check to measure Kintara Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kintara Therapeutics is operating at the current time. Most of Kintara Therapeutics' value examination focuses on studying past and present price action to predict the probability of Kintara Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kintara Therapeutics' price. Additionally, you may evaluate how the addition of Kintara Therapeutics to your portfolios can decrease your overall portfolio volatility.
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
AI Investment Finder
Use AI to screen and filter profitable investment opportunities
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
CEOs Directory
Screen CEOs from public companies around the world
Is Kintara Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kintara Therapeutics. If investors know Kintara will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kintara Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(5.22)
Return On Assets
(1.13)
Return On Equity
(3.29)
The market value of Kintara Therapeutics is measured differently than its book value, which is the value of Kintara that is recorded on the company's balance sheet. Investors also form their own opinion of Kintara Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Kintara Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kintara Therapeutics' market value can be influenced by many factors that don't directly affect Kintara Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kintara Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Kintara Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kintara Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.